Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986337 · 1 trial · 1 indication
PR interval is the time from the onset of the P wave to the start of the QRS complex
QRS can be defined as the electrical impulse as it spreads through the ventricles, indicating ventricular depolarization
QTcF = Corrected QT interval using the Fridericia formula. QT interval is the time from the start of the Q wave to the end of the T wave.
The QT interval is the time from the start of the Q wave to the end of the T wave.
| Arm | Type | Description |
|---|---|---|
| Part A Single Ascending Dose (SAD) Cohort A1 | EXPERIMENTAL | - |
| Part A SAD Cohort A2 | EXPERIMENTAL | - |
| Part A SAD Cohort A3 | EXPERIMENTAL | - |
| Part A SAD Cohort A4 | EXPERIMENTAL | - |
| Part A SAD Cohort A5 | EXPERIMENTAL | - |
| Part A SAD Cohort A6 | EXPERIMENTAL | - |
| Part B Multiple Ascending Dose (MAD) Cohort B1 | EXPERIMENTAL | - |
| Part B MAD Cohort B2 | EXPERIMENTAL | - |
| Part B MAD Cohort B3 | EXPERIMENTAL | - |
| Part B MAD Cohort B4 | EXPERIMENTAL | - |
| Part C MAD in Japanese Healthy participants Cohort C1 | EXPERIMENTAL | - |
| Part C MAD in Japanese Healthy participants Cohort C2 | EXPERIMENTAL | - |
| Part C MAD in Japanese Healthy participants Cohort C3 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-986337 | DRUG | Specified Dose on Specified Days |
| BMS-986337 Placebo | OTHER | Specified Dose on Specified Days |
| Famotidine | BIOLOGICAL | Specified Dose on Specified Days |
Inclusion Criteria: * No clinically significant deviation from normal in medical history, physical examination, electrocardiograms (ECGs), and clinical laboratory determinations * For Japanese cohorts in Part C, must be first-generation Japanese (born in Japan, not living outside of Japan for more ...
BMS-986337 is an investigational small molecule being developed by Bristol-Myers Squibb Company (NYSE: BMY). It has been studied in a Phase 1 clinical trial in healthy volunteers. The specific disease or condition it is intended to treat has not been disclosed, and it remains in early clinical development.
BMS-986337 is being developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker BMY. Bristol-Myers Squibb sponsored the Phase 1 study of the compound conducted in the Netherlands.
BMS-986337 is in Phase 1 development. One Phase 1 trial has been completed, and no active trials are currently listed. The compound has not been approved by the FDA and remains investigational.
BMS-986337 has been evaluated in one clinical trial, NCT04550195, titled "A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986337 When Taken by Mouth by Healthy Participants." The Phase 1 study enrolled 26 healthy volunteers in the Netherlands, was randomized, double-blind, and controlled, and is now completed.
No. BMS-986337 is an investigational drug in Phase 1 clinical development and has not been approved by the FDA. Its only completed trial studied safety, tolerability, and drug levels in healthy participants rather than in patients with a specific disease.
BMS-986337 is not yet approved for any use. It is an investigational small molecule that has completed a single Phase 1 trial in healthy volunteers, where researchers assessed its safety, tolerability, and drug levels when taken by mouth. The intended therapeutic indication has not been disclosed.